Structure Therapeutics(GPCR) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in fourth quarter of 2024 Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors Strong financial position with cash balance of $927.1 million expected to fund projected operation ...